Darbepoietin treatment of anemia secondary to chronic renal failure in dialysis;Estudio multicéntrico de darbepoetin alfa en el tratamiento de la anemia secundaria a insuficiencia renal crónica en diálisis

Nefrologia

Volumn 23, Issue 2, 2003, Pages 114-124

  Martinez Castelao A ^a   Reyes, A ^b   Valdes F ^c   Otero, A ^d   Lopez De Novales E ^e   Pallardo L ^f   Tabernero, J M ^g   Hernandez Jaras J ^h   Llados F ⁱ  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d Hospital Cristal Pinor   (Spain)

^e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^f HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h HOSPITAL GENERAL DE CASTELLÓN   (Spain)

ⁱ Bristol Meyers Squibb   (Portugal)

Author keywords

Anemia; Darbepoetin alfa; Dialysis; Erythropoiesis; r HuEPO; Renal failure

Indexed keywords

DARBEPOIETIN ALPHA; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MOLECULAR WEIGHT; MULTICENTER STUDY; PERITONEAL DIALYSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TITRIMETRY; BLEEDING; BLOOD; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; HEART INFARCTION; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; SAFETY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS; TREATMENT OUTCOME;

AGED; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HEMORRHAGE; HUMANS; HYPERTENSION; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RENAL DIALYSIS; SAFETY; THROMBOSIS; TREATMENT OUTCOME;

EID: 0038113264     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Valderrábano F: Anaemia management in chronic kidney disease patients: an overview of current clinical practice. Nephrol Dial Transplant 17 (Supl. 1): 13-18, 2002.
2. Levin A: Anaemia in the patient with renal insufficiency: documenting the impact and reviewing treatment strategies. Nephrol Dial Transplant 14 (2): 292-295, 1999.
3. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR y cols.: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25 (4): 548-554, 1995.
4. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y y cols.: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35 (2): 250-256, 2000.
5. Moreno F, Sanz-Guajardo D, López-Gómez JM, Jofre R, Valderrábano F: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 11 (2): 335-342, 2000.
6. MacDougall IC, Hutton RD, Coles GA, Williams JD: The use of erythropoietin in renal failure. Postgrad Med 3 67 (783): 9-15, 1991.
7. Eschbach M: Erythropoietin: the promise and the facts. Kidney Int Suppl 44: S70-76, 1994.
8. Besarab A: Physiological and pharmacodynamic considerations for route of EPO administration. Semin Nephrol 20(4):364-74, 2000.
9. Dordal MS, Wang FF, Goldwasser E: The role of carbohydrate in erythropoietin action. Endocrinology 116 (6): 2293-2299, 1985.
10. Egrie JC, Browne JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 (Supl. 3): 3-13, 2001.
11. Joy MS: Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Ann Pharmacother 36 (7): 1183-1192, 2002.
12. MacDougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J y cols.: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10 (11): 2392-2395, 1999.
13. MacDougall IC, Roberts DE, Coles GA, Williams JD: Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 20 (2): 99-113, 1991.
14. MacDougall IC: Darbepoetin alfa: a new therapeutic agent for renal anemia. Kidney Int Supl (80): 55-61, 2002.
15. Aljama P, Bommer J, Canaud B, Carrera F, Eckardt KU, Horl WH y cols.: Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 16 (Supl. 3): 22-28, 2001.
16. Hudson JQ, Sameri RM: Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease. Pharmacotherapy 22 (9 Pt 2): 141S-149S, 2002.
17. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C y cols.: Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60 (2): 741-747, 2001.
18. rd Annual Meeting American Society of Nephrology: SU624, 2000.
19. Ibbotson T, Goa KL: Darbepoetin alfa. Drugs 61 (14): 2097-2104; discussion 2105-6, 2001.
20. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C y cols.: Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 (1): 110-118, 2002.
21. rd Annual Meeting American Society of Nephrology: Oral presentation, 2000.
22. Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF y cols.: Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62 (6): 2167-2175, 2002.
23. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG y cols.: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339 (9): 578-583, 1998.
24. Besarab A, Reyes CM, Hornberger J: Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 (3): 439-446, 2002.
25. Locatelli F y cols.: Treatment of anemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (r-HuEPO). Nephrol Dial Transplant, in press.
26. Macdougall IC: An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 (Supl. 3): 14-21, 2001.
27. MacDougall IC: Novel erythropoiesis stimulating protein. Semin Nephrol 20 (4): 375-381, 2000.
28. MacDougall IC, Horl WH, Jacobs C, Valderrábano F, Parrondo I, Thompson K y cols.: European best practice guidelines 6-8: assessing and optimizing iron stores. Nephrol Dial Transplant 15 (Supl. 4): 20-32, 2000.
29. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30 (4 Supl. 3): S192-240, 1997.